Activation-induced cell death in human peripheral blood lymphocytes after stimulation with silicate in vitro.
Silica and related substances such as silicate have been proven to possess "adjuvant effects". We have previously reported a finding of polyclonal human T cell activation induced by silicate as a superantigen in vitro. In this study, we observed activation-induced cell death in human lymphocytes after stimulation with chrysotile, a kind of silicate. Apoptotic cells were detected flow cytometrically using the TUNEL assay, and the maximum appearance of TUNEL positive cells occurred on day 4 of incubation. Simultaneously the manifestation of small-sized cells in the specimens increased implying apoptosis. Fas expression on lymphocytes increased to day 3 of incubation with chrysotile, and then spontaneously decreased on day 4 when remarkable apoptosis could be detected. Based on these results it is conceivable that activation-induced cell death occurred through Fas-Fas ligand interaction in lymphocytes after stimulation with silicate in a concentration with which no acute cytotoxicity has been detected. Whether and how the repeated apoptosis in definite clones of lymphocytes causes the induction of sFas synthesis need clarification.
Aikoh
T
T
Department of Hygiene, Kawasaki Medical School, Kurashiki 701-01, Japan.
Tomokuni
A
A
Matsukii
T
T
Hyodoh
F
F
Ueki
H
H
Otsuki
T
T
Ueki
A
A
D017632:Asbestos, Serpentine / Q000494:pharmacology; D017252:CD3 Complex / Q000096:biosynthesis / Q000187:drug effects; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000502:physiology; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000502:physiology; D002273:Carcinogens / Q000008:administration & dosage / Q000494:pharmacology; D016923:Cell Death / Q000187:drug effects; D053222:Fas Ligand Protein; D006801:Humans; D018950:Lipopolysaccharide Receptors / Q000096:biosynthesis / Q000187:drug effects; D008213:Lymphocyte Activation / Q000187:drug effects; D008562:Membrane Glycoproteins / Q000096:biosynthesis / Q000187:drug effects; D017640:Silicates / Q000008:administration & dosage / Q000276:immunology / Q000494:pharmacology*; D018089:Superantigens / Q000494:pharmacology; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology* / Q000502:physiology
D017632:Asbestos, Serpentine; D017252:CD3 Complex; D002273:Carcinogens; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D018950:Lipopolysaccharide Receptors; D008562:Membrane Glycoproteins; D017640:Silicates; D018089:Superantigens